# targeted alpha therapy

China Installs First Superconducting Linac for Mass Production of Scarce Alpha Cancer Isotopes

China’s Institute of Modern Physics has installed the main accelerator for IP-SAFE, a superconducting linac demonstrator intended to mass-produce scarce alpha-emitting isotopes Ac-225 and Ra-223. The facility aims to ease global shortages that constrain targeted alpha therapies and to bolster domestic biomedical and accelerator capabilities.